Business Context and Reporting Period
This Form 8-K is a current report filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc., as indicated in the metadata) on June 9, 2017. The filing discloses the appointment of a new director to the Board of Directors and related compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Patricia S. Andrews as a director and member of the Audit Committee, effective June 9, 2017. Ms. Andrews will serve as a Class III director with a term expiring at the 2020 annual meeting of stockholders.
Guidance, Outlook, and Compensation Details
There is no financial guidance or outlook provided in this filing. Management commentary is limited to the background of the new director and the terms of her appointment. Key compensation details include:
- Stock Options: A grant of 22,000 nonqualified stock options at an exercise price of $11.63 per share, vesting in three equal installments over three years.
- Annual Retainer: $35,000 for board service and $7,500 for Audit Committee service.
- Future Grants: An additional option to purchase 11,000 shares will be granted at each subsequent annual stockholder meeting, vesting over one year.
Ms. Andrews brings significant experience, having served as CEO of Boston Biomedical, Inc. since April 2017 and previously holding senior roles at Incyte Corporation and Pfizer Inc.
Investor Verification Checklist
- Verify the exact date of the press release (June 12, 2017) referenced in Item 7.01 for additional context.
- Confirm the current stock price relative to the $11.63 exercise price of the granted options.
- Review the Company's 2013 Equity Incentive Plan for specific definitions of "Continuous Service" affecting vesting.
- Note that the registrant is an emerging growth company that has elected not to use the extended transition period for new accounting standards.